GPT and hepatocellular carcinoma: On subgroup analysis with patients with HBV DNA > 2000 IU/mL and ALT ≥ 2 × ULN, those who received treatment continued to have a significantly lower incidence of HCC compared to those who were not treated, after adjustment with REACH-B score (P = 0.0419).